Baseline serum glycoprotein acetylation predicts early but not late relapse after infliximab withdrawal in Crohn's disease: metabolomic analysis of the STORI and SPARE trials.
- DOI
- 10.1053/j.gastro.2026.10.381
- Published
- 2026 Nov 6
- Container
- Gastroenterology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1053/j.gastro.2026.10.381,
title = {Baseline serum glycoprotein acetylation predicts early but not late relapse after infliximab withdrawal in Crohn's disease: metabolomic analysis of the STORI and SPARE trials.},
author = {Radford-Smith DE and Anthony DC and Probert F and Colombel JF and Satsangi J and Louis E and GETAID (Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif)},
year = {2026},
journal = {Gastroenterology},
doi = {10.1053/j.gastro.2026.10.381},
url = {https://doi.org/10.1053/j.gastro.2026.10.381}
}RIS
TY - JOUR TI - Baseline serum glycoprotein acetylation predicts early but not late relapse after infliximab withdrawal in Crohn's disease: metabolomic analysis of the STORI and SPARE trials. AU - Radford-Smith DE AU - Anthony DC AU - Probert F AU - Colombel JF AU - Satsangi J AU - Louis E AU - GETAID (Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif) PY - 2026 JO - Gastroenterology DO - 10.1053/j.gastro.2026.10.381 UR - https://doi.org/10.1053/j.gastro.2026.10.381 ER -
APA
DE, R., DC, A., F, P., JF, C., J, S., E, L., & Digestif), G. (. D. T. D. A. I. D. T. (2026). Baseline serum glycoprotein acetylation predicts early but not late relapse after infliximab withdrawal in Crohn's disease: metabolomic analysis of the STORI and SPARE trials.. Gastroenterology. https://doi.org/10.1053/j.gastro.2026.10.381
Source records
- pubmed · retrieved 2026-11-10T20:07:45.072Z